THE BERMES PROJECT INCLUDED IN THE ORPHANET DATABASE
Orphanet is the reference information portal on rare diseases and orphan drugs aimed at all audiences. The aim of Orphanet is to contribute to the improvement of the diagnosis, care and treatment of patients with rare diseases.
Due to its incidence, malignant mesothelioma is considered a rare disease and therefore, the medicines developed to treat it are considered orphan drugs. One of the objectives of Aromics through its project BERMES, is to advance on the development of the candidate drug NAX035 towards an early clinical stage for this rare disease.